Literature DB >> 26063476

Use of common analgesics is not associated with ovarian cancer survival.

Albina N Minlikeeva1, Jo L Freudenheim1, Wei-Hsuan Lo-Ciganic2, Kevin H Eng3, Grace Friel4, Brenda Diergaarde5, Francesmary Modugno6, Rikki Cannioto4, Emily Gower4, J Brian Szender7, Kassondra Grzankowski7, Kunle Odunsi7, Roberta B Ness8, Kirsten B Moysich9.   

Abstract

BACKGROUND: Use of analgesics has been associated with lower risk of ovarian cancer, but, to date, very few studies have explored the association between analgesics and ovarian cancer survival.
METHODS: We examined the relationship between self-reported prediagnostic use of aspirin, ibuprofen, and acetaminophen and overall survival (OS), progression-free survival (PFS), ascites at the time of primary treatment, and persistence of disease after primary treatment among 699 women diagnosed with epithelial ovarian carcinoma. The associations between use of these medications and OS and PFS were estimated using Cox proportional hazards models. We utilized unconditional logistic regression models to estimate associations between medication use and presence of ascites and persistence of disease.
RESULTS: Prediagnostic intake of aspirin, both low-dose and regular-dose, ibuprofen, and acetaminophen was not associated with any of the outcomes of interest.
CONCLUSIONS: Our results indicate a lack of association between prediagnostic intake of selected analgesics and OS, PFS, presence of ascites at the time of primary treatment, and persistence of disease after primary treatment. IMPACT: Prediagnostic intake of analgesics may not be associated with ovarian cancer outcomes. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26063476      PMCID: PMC4526413          DOI: 10.1158/1055-9965.EPI-15-0508

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  8 in total

1.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival.

Authors:  Christina M Nagle; Torukiri I Ibiebele; Anna DeFazio; Melinda M Protani; Penelope M Webb
Journal:  Cancer Epidemiol       Date:  2015-02-07       Impact factor: 2.984

2.  Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.

Authors:  Cristina Rodríguez-Burford; Mack N Barnes; Denise K Oelschlager; Russell B Myers; Lynya I Talley; Edward E Partridge; William E Grizzle
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

Review 3.  Inflammation and ovarian cancer.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  Cytokine       Date:  2012-02-19       Impact factor: 3.861

4.  Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer.

Authors:  Roberta B Ness; Rhiannon C Dodge; Robert P Edwards; Julie A Baker; Kirsten B Moysich
Journal:  Ann Epidemiol       Date:  2010-12-15       Impact factor: 3.797

Review 5.  Possible role of ovarian epithelial inflammation in ovarian cancer.

Authors:  R B Ness; C Cottreau
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

Review 6.  Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.

Authors:  Louise Baandrup; Mette T Faber; Jane Christensen; Allan Jensen; Klaus K Andersen; Søren Friis; Susanne K Kjaer
Journal:  Acta Obstet Gynecol Scand       Date:  2013-01-22       Impact factor: 3.636

7.  Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.

Authors:  J S Lee; Y D Choi; J H Lee; J H Nam; C Choi; M C Lee; C S Park; S W Juhng; K W Min
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

8.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 11.816

  8 in total
  4 in total

1.  Anthropometric characteristics and ovarian cancer risk and survival.

Authors:  Albina N Minlikeeva; Kirsten B Moysich; Paul C Mayor; John L Etter; Rikki A Cannioto; Roberta B Ness; Kristen Starbuck; Robert P Edwards; Brahm H Segal; Sashikant Lele; Kunle Odunsi; Brenda Diergaarde; Francesmary Modugno
Journal:  Cancer Causes Control       Date:  2018-01-11       Impact factor: 2.506

2.  Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Suzanne C Dixon; Christina M Nagle; Nicolas Wentzensen; Britton Trabert; Alicia Beeghly-Fadiel; Joellen M Schildkraut; Kirsten B Moysich; Anna deFazio; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Robert P Edwards; Allan Jensen; Susanne K Kjær; Estrid Høgdall; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Elizabeth M Poole; Elisa V Bandera; Lisa E Paddock; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste Leigh Pearce; Anna H Wu; Malcolm C Pike; Penelope M Webb
Journal:  Br J Cancer       Date:  2017-03-28       Impact factor: 7.640

3.  Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.

Authors:  Freija Verdoodt; Susanne K Kjaer; Christian Dehlendorff; Søren Friis
Journal:  Br J Cancer       Date:  2018-01-09       Impact factor: 7.640

4.  Aspirin use correlates with survival in women with clear cell ovarian cancer.

Authors:  Alyssa M Wield; Christine S Walsh; B J Rimel; Ilana Cass; Beth Y Karlan; Andrew J Li
Journal:  Gynecol Oncol Rep       Date:  2018-06-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.